Cargando…

Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma

BACKGROUND: Lung adenocarcinoma (LUAD) is one of the leading contributors to cancer‐related deaths worldwide. The objective of the current study is to identify a multidimensional transcriptome prognostic signature by combining protein‐coding gene (PCG) with long non‐coding RNA (lncRNA) for patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Jing, Liu, Hui, Xu, Zhi‐Li, Zheng, Ling, Liu, Rong‐Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868416/
https://www.ncbi.nlm.nih.gov/pubmed/31402485
http://dx.doi.org/10.1002/jcla.22990
_version_ 1783472257943732224
author Ye, Jing
Liu, Hui
Xu, Zhi‐Li
Zheng, Ling
Liu, Rong‐Yu
author_facet Ye, Jing
Liu, Hui
Xu, Zhi‐Li
Zheng, Ling
Liu, Rong‐Yu
author_sort Ye, Jing
collection PubMed
description BACKGROUND: Lung adenocarcinoma (LUAD) is one of the leading contributors to cancer‐related deaths worldwide. The objective of the current study is to identify a multidimensional transcriptome prognostic signature by combining protein‐coding gene (PCG) with long non‐coding RNA (lncRNA) for patients with LUAD. METHODS: We obtained LUAD PCG and lncRNA expression profile data from three datasets in the Gene Expression Omnibus database and conducted survival analyzes for these individuals. RESULTS: We established a predictive model comprising the three PCGs (NHLRC2, PLIN5, GNAI3), and one lncRNA (AC087521.1). This model segregated patients with LUAD into low‐ and high‐risk groups based on significant differences in survival in the training dataset (GSE31210, n = 226, log‐rank test P < .001). Risk stratification of the model was subsequently validated in other two test datasets (GSE37745, n = 106, log‐rank test P < .001; GSE30219, n = 85, log‐rank test P = .006). Time‐dependent receiver operating characteristic (timeROC) curve analysis demonstrated that the model correlated strongly with disease progression and outperformed pathological stage in terms of prognostic ability. Cox proportional hazards regression analysis revealed that the signature could serve as an independent predictor of clinical outcomes in patients with LUAD. CONCLUSIONS: We describe a novel multidimensional transcriptome signature that can predict survival probabilities in patients with LUAD.
format Online
Article
Text
id pubmed-6868416
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-68684162019-11-25 Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma Ye, Jing Liu, Hui Xu, Zhi‐Li Zheng, Ling Liu, Rong‐Yu J Clin Lab Anal Research Articles BACKGROUND: Lung adenocarcinoma (LUAD) is one of the leading contributors to cancer‐related deaths worldwide. The objective of the current study is to identify a multidimensional transcriptome prognostic signature by combining protein‐coding gene (PCG) with long non‐coding RNA (lncRNA) for patients with LUAD. METHODS: We obtained LUAD PCG and lncRNA expression profile data from three datasets in the Gene Expression Omnibus database and conducted survival analyzes for these individuals. RESULTS: We established a predictive model comprising the three PCGs (NHLRC2, PLIN5, GNAI3), and one lncRNA (AC087521.1). This model segregated patients with LUAD into low‐ and high‐risk groups based on significant differences in survival in the training dataset (GSE31210, n = 226, log‐rank test P < .001). Risk stratification of the model was subsequently validated in other two test datasets (GSE37745, n = 106, log‐rank test P < .001; GSE30219, n = 85, log‐rank test P = .006). Time‐dependent receiver operating characteristic (timeROC) curve analysis demonstrated that the model correlated strongly with disease progression and outperformed pathological stage in terms of prognostic ability. Cox proportional hazards regression analysis revealed that the signature could serve as an independent predictor of clinical outcomes in patients with LUAD. CONCLUSIONS: We describe a novel multidimensional transcriptome signature that can predict survival probabilities in patients with LUAD. John Wiley and Sons Inc. 2019-08-11 /pmc/articles/PMC6868416/ /pubmed/31402485 http://dx.doi.org/10.1002/jcla.22990 Text en © 2019 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research Articles
Ye, Jing
Liu, Hui
Xu, Zhi‐Li
Zheng, Ling
Liu, Rong‐Yu
Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
title Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
title_full Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
title_fullStr Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
title_full_unstemmed Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
title_short Identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
title_sort identification of a multidimensional transcriptome prognostic signature for lung adenocarcinoma
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868416/
https://www.ncbi.nlm.nih.gov/pubmed/31402485
http://dx.doi.org/10.1002/jcla.22990
work_keys_str_mv AT yejing identificationofamultidimensionaltranscriptomeprognosticsignatureforlungadenocarcinoma
AT liuhui identificationofamultidimensionaltranscriptomeprognosticsignatureforlungadenocarcinoma
AT xuzhili identificationofamultidimensionaltranscriptomeprognosticsignatureforlungadenocarcinoma
AT zhengling identificationofamultidimensionaltranscriptomeprognosticsignatureforlungadenocarcinoma
AT liurongyu identificationofamultidimensionaltranscriptomeprognosticsignatureforlungadenocarcinoma